{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["arbutin", "bile acid metabolism", "cholestasis", "farnesoid X receptor", "liver injury", "ursodeoxycholic acid", "\u03b1-naphthylisothiocyanate"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "34926449", "DateRevised": {"Year": "2021", "Month": "12", "Day": "21"}, "Article": {"ArticleDate": [{"Year": "2021", "Month": "12", "Day": "02"}], "Language": ["eng"], "ELocationID": ["758632", "10.3389/fcell.2021.758632"], "Journal": {"ISSN": "2296-634X", "JournalIssue": {"Volume": "9", "PubDate": {"Year": "2021"}}, "Title": "Frontiers in cell and developmental biology", "ISOAbbreviation": "Front Cell Dev Biol"}, "ArticleTitle": "Arbutin Alleviates the Liver Injury of <i>\u03b1</i>-Naphthylisothiocyanate-induced Cholestasis Through Farnesoid X Receptor Activation.", "Pagination": {"StartPage": "758632", "MedlinePgn": "758632"}, "Abstract": {"AbstractText": ["Cholestasis is a kind of stressful syndrome along with liver toxicity, which has been demonstrated to be related to fibrosis, cirrhosis, even cholangiocellular or hepatocellular carcinomas. Cholestasis usually caused by the dysregulated metabolism of bile acids that possess high cellular toxicity and synthesized by cholesterol in the liver to undergo enterohepatic circulation. In cholestasis, the accumulation of bile acids in the liver causes biliary and hepatocyte injury, oxidative stress, and inflammation. The farnesoid X receptor (FXR) is regarded as a bile acid-activated receptor that regulates a network of genes involved in bile acid metabolism, providing a new therapeutic target to treat cholestatic diseases. Arbutin is a glycosylated hydroquinone isolated from medicinal plants in the genus <i>Arctostaphylos</i>, which has a variety of potentially pharmacological properties, such as anti-inflammatory, antihyperlipidemic, antiviral, antihyperglycemic, and antioxidant activity. However, the mechanistic contributions of arbutin to alleviate liver injury of cholestasis, especially its role on bile acid homeostasis via nuclear receptors, have not been fully elucidated. In this study, we demonstrate that arbutin has a protective effect on <i>\u03b1</i>-naphthylisothiocyanate-induced cholestasis via upregulation of the levels of FXR and downstream enzymes associated with bile acid homeostasis such as Bsep, Ntcp, and Sult2a1, as well as Ugt1a1. Furthermore, the regulation of these functional proteins related to bile acid homeostasis by arbutin could be alleviated by FXR silencing in L-02 cells. In conclusion, a protective effect could be supported by arbutin to alleviate ANIT-induced cholestatic liver toxicity, which was partly through the FXR pathway, suggesting arbutin may be a potential chemical molecule for the cholestatic disease."], "CopyrightInformation": "Copyright \u00a9 2021 Wu, Qiao, Yu, Ming, Liu, Wu and Li."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, China."}], "LastName": "Wu", "ForeName": "Peijie", "Initials": "P"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, China."}], "LastName": "Qiao", "ForeName": "Ling", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, China."}], "LastName": "Yu", "ForeName": "Han", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, China."}], "LastName": "Ming", "ForeName": "Hui", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, China."}], "LastName": "Liu", "ForeName": "Chao", "Initials": "C"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, China."}], "LastName": "Wu", "ForeName": "Wenjun", "Initials": "W"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, China."}], "LastName": "Li", "ForeName": "Baixue", "Initials": "B"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Front Cell Dev Biol", "NlmUniqueID": "101630250", "ISSNLinking": "2296-634X"}, "CoiStatement": "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Al-Aqil F. A., Monte M. J., Peleteiro-Vigil A., Briz O., Rosales R., Gonz\u00e1lez R., et al. (2018). Interaction of Glucocorticoids with FXR/FGF19/FGF21-mediated Ileum-Liver Crosstalk. Biochim. Biophys. Acta (Bba) - Mol. Basis Dis. 1864(9 Pt B), 2927\u20132937. 10.1016/j.bbadis.2018.06.003", "ArticleIdList": ["10.1016/j.bbadis.2018.06.003", "29883717"]}, {"Citation": "Alrefai W. A., Gill R. K. (2007). Bile Acid Transporters: Structure, Function, Regulation and Pathophysiological Implications. Pharm. Res. 24(10), 1803\u20131823. 10.1007/s11095-007-9289-1", "ArticleIdList": ["10.1007/s11095-007-9289-1", "17404808"]}, {"Citation": "Bertaggia E., Jensen K. K., Castro-Perez J., Xu Y., Di Paolo G., Chan R. B., et al. (2017). Cyp8b1 Ablation Prevents Western Diet-Induced Weight Gain and Hepatic Steatosis Because of Impaired Fat Absorption. Am. J. Physiology-Endocrinology Metab. 313(2), E121-e133. 10.1152/ajpendo.00409.2016", "ArticleIdList": ["10.1152/ajpendo.00409.2016", "PMC5582885", "28377401"]}, {"Citation": "Carino A., Biagioli M., Marchian\u00f2 S., Fiorucci C., Bordoni M., Roselli R., et al. (2020). Opposite Effects of the FXR Agonist Obeticholic Acid on Mafg and Nrf2 Mediate the Development of Acute Liver Injury in Rodent Models of Cholestasis. Biochim. Biophys. Acta (Bba) - Mol. Cel Biol. Lipids 1865(9), 158733. 10.1016/j.bbalip.2020.158733", "ArticleIdList": ["10.1016/j.bbalip.2020.158733", "32371093"]}, {"Citation": "Carpenter-Deyo L., Marchand D. H., Jean P. A., Roth R. A., Reed D. J. (1991). Involvement of Glutathione in 1-naphthylisothiocyanate (ANIT) Metabolism and Toxicity to Isolated Hepatocytes. Biochem. Pharmacol. 42(11), 2171\u20132180. 10.1016/0006-2952(91)90353-7", "ArticleIdList": ["10.1016/0006-2952(91)90353-7", "1958235"]}, {"Citation": "Chambers K. F., Day P. E., Aboufarrag H. T., Kroon P. A. (2019). Polyphenol Effects on Cholesterol Metabolism via Bile Acid Biosynthesis, CYP7A1: A Review. Nutrients 11(11, 2588). 10.3390/nu11112588", "ArticleIdList": ["10.3390/nu11112588", "PMC6893479", "31661763"]}, {"Citation": "Corpechot C., Chazouill\u00e8res O., Belnou P., Montano-Loza A. J., Mason A., Ebadi M., et al. (2020). Long-term Impact of Preventive UDCA Therapy after Transplantation for Primary Biliary Cholangitis. J. Hepatol. 73(3), 559\u2013565. 10.1016/j.jhep.2020.03.043", "ArticleIdList": ["10.1016/j.jhep.2020.03.043", "32275981"]}, {"Citation": "Dong R., Yang X., Wang C., Liu K., Liu Z., Ma X., et al. (2019). Yangonin Protects against Non-alcoholic Fatty Liver Disease through Farnesoid X Receptor. Phytomedicine 53 , 134\u2013142. 10.1016/j.phymed.2018.09.006", "ArticleIdList": ["10.1016/j.phymed.2018.09.006", "30668392"]}, {"Citation": "Dyson J. K., Jones D. E. J. (2020). UDCA Prophylaxis for post-transplant PBC Recurrence Prevention: Time to Change Practice. J. Hepatol. 73(3), 499\u2013501. 10.1016/j.jhep.2020.04.040", "ArticleIdList": ["10.1016/j.jhep.2020.04.040", "32576471"]}, {"Citation": "Feldman A. G., Sokol R. J. (2020). Recent Developments in Diagnostics and Treatment of Neonatal Cholestasis. Semin. Pediatr. Surg. 29(4), 150945. 10.1016/j.sempedsurg.2020.150945", "ArticleIdList": ["10.1016/j.sempedsurg.2020.150945", "PMC7459146", "32861449"]}, {"Citation": "Floreani A., Mangini C. (2018). Primary Biliary Cholangitis: Old and Novel Therapy. Eur. J. Intern. Med. 47 , 1\u20135. 10.1016/j.ejim.2017.06.020", "ArticleIdList": ["10.1016/j.ejim.2017.06.020", "28669591"]}, {"Citation": "Gao L., Wang L., Woo E., He X., Yang G., Bowlus C., et al. (2020). Clinical Management of Primary Biliary Cholangitis-Strategies and Evolving Trends. Clinic Rev. Allerg Immunol. 59(2), 175\u2013194. 10.1007/s12016-019-08772-7", "ArticleIdList": ["10.1007/s12016-019-08772-7", "31713023"]}, {"Citation": "Garcia-Jimenez A., Teruel-Puche J. A., Berna J., Rodriguez-Lopez J. N., Tudela J., Garcia-Canovas F. (2017). Action of Tyrosinase on Alpha and Beta-Arbutin: A Kinetic Study. PLoS One 12(5), e0177330. 10.1371/journal.pone.0177330", "ArticleIdList": ["10.1371/journal.pone.0177330", "PMC5426667", "28493937"]}, {"Citation": "Goldstein J., Levy C. (2018). Novel and Emerging Therapies for Cholestatic Liver Diseases. Liver Int. 38(9), 1520\u20131535. 10.1111/liv.13880", "ArticleIdList": ["10.1111/liv.13880", "29758112"]}, {"Citation": "Halilbasic E., Claudel T., Trauner M. (2013). Bile Acid Transporters and Regulatory Nuclear Receptors in the Liver and beyond. J. Hepatol. 58(1), 155\u2013168. 10.1016/j.jhep.2012.08.002", "ArticleIdList": ["10.1016/j.jhep.2012.08.002", "PMC3526785", "22885388"]}, {"Citation": "Hirschfield G. M., Karlsen T. H., Lindor K. D., Adams D. H. (2013). Primary Sclerosing Cholangitis. The Lancet 382(9904), 1587\u20131599. 10.1016/s0140-6736(13)60096-3", "ArticleIdList": ["10.1016/s0140-6736(13)60096-3", "23810223"]}, {"Citation": "Jahan A., Chiang J. Y. L. (2005). Cytokine Regulation of Human Sterol 12\u03b1-Hydroxylase (CYP8B1) Gene. Am. J. Physiology-Gastrointestinal Liver Physiol. 288(4), G685\u2013G695. 10.1152/ajpgi.00207.2004", "ArticleIdList": ["10.1152/ajpgi.00207.2004", "15550563"]}, {"Citation": "Jurica K., Benkovi\u0107 V., Sikiri\u0107 S., Kopjar N., Br\u010di\u0107 Kara\u010donji I. (2020). Liver Function and DNA Integrity in Hepatocytes of Rats Evaluated after Treatments with Strawberry Tree (Arbutus Unedo L.) Water Leaf Extract and Arbutin. Drug Chem. Toxicol. 43(2), 127\u2013137. 10.1080/01480545.2018.1477794", "ArticleIdList": ["10.1080/01480545.2018.1477794", "29874937"]}, {"Citation": "Keitel V., Dr\u00f6ge C., H\u00e4ussinger D. (2019). Targeting FXR in Cholestasis. Handb Exp. Pharmacol. 256 , 299\u2013324. 10.1007/164_2019_231", "ArticleIdList": ["10.1007/164_2019_231", "31201556"]}, {"Citation": "Kj\u00e6rgaard K., Frisch K., S\u00f8rensen M., Munk O. L., Hofmann A. F., Horsager J., et al. (2021). Obeticholic Acid Improves Hepatic Bile Acid Excretion in Patients with Primary Biliary Cholangitis. J. Hepatol. 74(1), 58\u201365. 10.1016/j.jhep.2020.07.028", "ArticleIdList": ["10.1016/j.jhep.2020.07.028", "32717289"]}, {"Citation": "Kudlinzki D., Merk D., Linhard V., Saxena K., Schubert-Zsilavecz M., Schwalbe H. (2019). \"Crystal Structure of Farnesoid X Receptor (FXR) with Bound NCoA-2 Peptide and CDCA\")."}, {"Citation": "Kumar P., Kulkarni A. (2020). UDCA Therapy in Intrahepatic Cholestasis of Pregnancy? J. Hepatol. 72(3), 586\u2013587. 10.1016/j.jhep.2019.10.025", "ArticleIdList": ["10.1016/j.jhep.2019.10.025", "31864669"]}, {"Citation": "L\u00f3pez-Riera M., Conde I., Castell J. V., Jover R. (2020). A Novel MicroRNA Signature for Cholestatic Drugs in Human Hepatocytes and its Translation into Novel Circulating Biomarkers for Drug-Induced Liver Injury Patients. Toxicol. Sci. 173(2), 229\u2013243. 10.1093/toxsci/kfz138", "ArticleIdList": ["10.1093/toxsci/kfz138", "31198949"]}, {"Citation": "Li T., Chiang J. Y. L. (2020). Bile Acid-Based Therapies for Non-alcoholic Steatohepatitis and Alcoholic Liver Disease. Hepatobiliary Surg. Nutr. 9(2), 152\u2013169. 10.21037/hbsn.2019.09.03", "ArticleIdList": ["10.21037/hbsn.2019.09.03", "PMC7188552", "32355674"]}, {"Citation": "Li T., Xu L., Zheng R., Wang X., Li L., Ji H., et al. (2020a). Picroside II Protects against Cholestatic Liver Injury Possibly through Activation of Farnesoid X Receptor. Phytomedicine 68, 153153. 10.1016/j.phymed.2019.153153", "ArticleIdList": ["10.1016/j.phymed.2019.153153", "32018210"]}, {"Citation": "Li T., Zheng R., Xu L., Zhou M., Wang X., Guo Q., et al. (2020b). Picroside II Alleviates Liver Injury Induced by Alpha-Naphthylisothiocyanate through AMPK-FXR Pathway. Toxicol. Appl. Pharmacol. 408, 115248. 10.1016/j.taap.2020.115248", "ArticleIdList": ["10.1016/j.taap.2020.115248", "32976922"]}, {"Citation": "Li W.-K., Wang G.-F., Wang T.-M., Li Y.-Y., Li Y.-F., Lu X.-Y., et al. (2019). Protective Effect of Herbal Medicine Huangqi Decoction against Chronic Cholestatic Liver Injury by Inhibiting Bile Acid-Stimulated Inflammation in DDC-Induced Mice. Phytomedicine 62, 152948. 10.1016/j.phymed.2019.152948", "ArticleIdList": ["10.1016/j.phymed.2019.152948", "31129431"]}, {"Citation": "Li X., Liu R., Yu L., Yuan Z., Sun R., Yang H., et al. (2016). Alpha-naphthylisothiocyanate Impairs Bile Acid Homeostasis through AMPK-FXR Pathways in Rat Primary Hepatocytes. Toxicology 370 , 106\u2013115. 10.1016/j.tox.2016.09.020", "ArticleIdList": ["10.1016/j.tox.2016.09.020", "27702592"]}, {"Citation": "Lindpaintner E. (1939). Arbutin und Methylarbutin und ihre Bestimmung in Drogen. Mit Unterst\u00fctzung der Deutschen Forschungsgemeinschaft. Arch. Pharm. Pharm. Med. Chem. 277(9), 398\u2013415. 10.1002/ardp.19392770903", "ArticleIdList": ["10.1002/ardp.19392770903"]}, {"Citation": "Mariotti V., Strazzabosco M., Fabris L., Calvisi D. F. (2018). Animal Models of Biliary Injury and Altered Bile Acid Metabolism. Biochim. Biophys. Acta (Bba) - Mol. Basis Dis. 1864(4 Pt B), 1254\u20131261. 10.1016/j.bbadis.2017.06.027", "ArticleIdList": ["10.1016/j.bbadis.2017.06.027", "PMC5764833", "28709963"]}, {"Citation": "Meier P. J., Stieger B. (2002). Bile Salt Transporters. Annu. Rev. Physiol. 64 , 635\u2013661. 10.1146/annurev.physiol.64.082201.100300", "ArticleIdList": ["10.1146/annurev.physiol.64.082201.100300", "11826283"]}, {"Citation": "Migas P., Krauze-Baranowska M. (2015). The Significance of Arbutin and its Derivatives in Therapy and Cosmetics. Phytochemistry Lett. 13 , 35\u201340. 10.1016/j.phytol.2015.05.015", "ArticleIdList": ["10.1016/j.phytol.2015.05.015"]}, {"Citation": "Mirshahvalad S., Feizi F., Barkhordar A., Bahadoram M., Houshmand G., Pouramir M. (2016). Hepatoprotective Effects of Arbutin against Liver Damage Induced by Carbon Tetrachloride in Rats. Jundishapur J. Nat. Pharm. Prod. 11(3), e33392. 10.17795/jjnpp.33392", "ArticleIdList": ["10.17795/jjnpp.33392"]}, {"Citation": "Nadi S., Elahi M., Moradi S., Banaei A., Ataei G., Abedi-Firouzjah R. (2019). Radioprotective Effect of Arbutin in Megavoltage Therapeutic X-Irradiated Mice Using Liver Enzymes Assessment. J. Biomed. Phys. Eng. 9(5), 533\u2013540. 10.31661/jbpe.v0i0.1199", "ArticleIdList": ["10.31661/jbpe.v0i0.1199", "PMC6820023", "31750267"]}, {"Citation": "Nakanishi Y., Saxena R. (2015). Pathophysiology and Diseases of the Proximal Pathways of the Biliary System. Arch. Pathol. Lab. Med. 139(7), 858\u2013866. 10.5858/arpa.2014-0229-RA", "ArticleIdList": ["10.5858/arpa.2014-0229-RA", "26125426"]}, {"Citation": "Navaneethan U., Spencer C., Zhu X., Vargo J. J., Grove D., Dweik R. A. (2021). Volatile Organic Compounds in Bile Can Distinguish Pancreatic Cancer from Chronic Pancreatitis: a Prospective Observational Study. Endoscopy 53(7), 732\u2013736. 10.1055/a-1255-9169", "ArticleIdList": ["10.1055/a-1255-9169", "32894868"]}, {"Citation": "Ocvirk S., O\u2019Keefe S. J. D. (2021). Dietary Fat, Bile Acid Metabolism and Colorectal Cancer. Semin. Cancer Biol. 73 , 347\u2013355. 10.1016/j.semcancer.2020.10.003", "ArticleIdList": ["10.1016/j.semcancer.2020.10.003", "33069873"]}, {"Citation": "Ortiz-Ruiz C. V., Garcia-Molina M. D. M., Serrano J. T., Tomas-Martinez V., Garcia-Canovas F. (2015). Discrimination between Alternative Substrates and Inhibitors of Tyrosinase. J. Agric. Food Chem. 63(8), 2162\u20132171. 10.1021/jf5051816", "ArticleIdList": ["10.1021/jf5051816", "25665009"]}, {"Citation": "Pathak R. D., Schroeder E. B., Seaquist E. R., Zeng C., Lafata J. E., Thomas A., et al. (2017). Erratum. Response to Comment on Pathak et al. Severe Hypoglycemia Requiring Medical Intervention in a Large Cohort of Adults With Diabetes Receiving Care in U.S. Integrated Health Care Delivery Systems: 2005-2011. Diabetes Care 2016;39:363-370. Diabetes Care 2017;40:e26. Dia Care 2016;39:1\u20131420. Diabetes Care 2017;40:e26. Diabetes Care 40(10), 1420. 10.2337/dc17-er10", "ArticleIdList": ["10.2337/dc17-er10", "PMC5606309", "28842525"]}, {"Citation": "Petrov P. D., Fern\u00e1ndez-Murga L., Conde I., Mart\u00ednez-Sena T., Guzm\u00e1n C., Castell J. V., et al. (2020). Epistane, an Anabolic Steroid Used for Recreational Purposes, Causes Cholestasis with Elevated Levels of Cholic Acid Conjugates, by Upregulating Bile Acid Synthesis (CYP8B1) and Cross-Talking with Nuclear Receptors in Human Hepatocytes. Arch. Toxicol. 94(2), 589\u2013607. 10.1007/s00204-019-02643-y", "ArticleIdList": ["10.1007/s00204-019-02643-y", "31894354"]}, {"Citation": "Rimland C. A., Tilson S. G., Morell C. M., Tomaz R. A., Lu W. Y., Adams S. E., et al. (2021). Regional Differences in Human Biliary Tissues and Corresponding In Vitro -Derived Organoids. Hepatology 73(1), 247\u2013267. 10.1002/hep.31252", "ArticleIdList": ["10.1002/hep.31252", "PMC8641381", "32222998"]}, {"Citation": "Santamar\u00eda E., Rodr\u00edguez-Ortigosa C. M., Uriarte I., Latasa M. U., Urtasun R., Alvarez-Sola G., et al. (2019). The Epidermal Growth Factor Receptor Ligand Amphiregulin Protects from Cholestatic Liver Injury and Regulates Bile Acids Synthesis. Hepatology 69(4), 1632\u20131647. 10.1002/hep.30348", "ArticleIdList": ["10.1002/hep.30348", "30411380"]}, {"Citation": "Stofan M., Guo G. L. (2020). Bile Acids and FXR: Novel Targets for Liver Diseases. Front. Med. (Lausanne) 7 , 544. 10.3389/fmed.2020.00544", "ArticleIdList": ["10.3389/fmed.2020.00544", "PMC7516013", "33015098"]}, {"Citation": "Tang H. C., Chen Y. C. (2015). Identification of Tyrosinase Inhibitors from Traditional Chinese Medicines for the Management of Hyperpigmentation. Springerplus 4 , 184. 10.1186/s40064-015-0956-0", "ArticleIdList": ["10.1186/s40064-015-0956-0", "PMC4411401", "25932370"]}, {"Citation": "Thakare R., Alamoudi J. A., Gautam N., Rodrigues A. D., Alnouti Y. (2018). Species Differences in Bile Acids I. Plasma and Urine Bile Acid Composition. J. Appl. Toxicol. 38(10), 1323\u20131335. 10.1002/jat.3644", "ArticleIdList": ["10.1002/jat.3644", "29785833"]}, {"Citation": "Wu P., Gao W., Su M., Nice E. C., Zhang W., Lin J., et al. (2021). Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment. Front Cel Dev Biol 9 , 641469. 10.3389/fcell.2021.641469", "ArticleIdList": ["10.3389/fcell.2021.641469", "PMC7957022", "33732706"]}, {"Citation": "Xu G., Li H., Pan L. X., Shang Q., Honda A., Ananthanarayanan M., et al. (2003). FXR-mediated Down-Regulation of CYP7A1 Dominates LXRalpha in Long-Term Cholesterol-Fed NZW Rabbits. J. Lipid Res. 44(10), 1956\u20131962. 10.1194/jlr.M300182-JLR200", "ArticleIdList": ["10.1194/jlr.M300182-JLR200", "12897188"]}, {"Citation": "Xu W. H., Liang Q., Zhang Y. J., Zhao P. (2015). Naturally Occurring Arbutin Derivatives and Their Bioactivities. Chem. Biodivers 12(1), 54\u201381. 10.1002/cbdv.201300269", "ArticleIdList": ["10.1002/cbdv.201300269", "25641837"]}, {"Citation": "Yu L., Lu H., Yang X., Li R., Shi J., Yu Y., et al. (2021). Diosgenin Alleviates Hypercholesterolemia via SRB1/CES-1/CYP7A1/FXR Pathway in High-Fat Diet-Fed Rats. Toxicol. Appl. Pharmacol. 412 , 115388. 10.1016/j.taap.2020.115388", "ArticleIdList": ["10.1016/j.taap.2020.115388", "33383043"]}, {"Citation": "Zhang G., Sun X., Wen Y., Shi A., Zhang J., Wei Y., et al. (2020). Hesperidin Alleviates Cholestasis via Activation of the Farnesoid X Receptor In Vitro and In Vivo . Eur. J. Pharmacol. 885 , 173498. 10.1016/j.ejphar.2020.173498", "ArticleIdList": ["10.1016/j.ejphar.2020.173498", "32841642"]}, {"Citation": "Zhou H., Zhao J., Li A., Reetz M. T. (2019). Chemical and Biocatalytic Routes to Arbutin (\u2020). Molecules 24(18). 10.3390/molecules24183303", "ArticleIdList": ["10.3390/molecules24183303", "PMC6766929", "31514332"]}, {"Citation": "Zollner G., Trauner M. (2008). Mechanisms of Cholestasis. Clin. Liver Dis. 12(1), 1\u201326. vii. 10.1016/j.cld.2007.11.010", "ArticleIdList": ["10.1016/j.cld.2007.11.010", "18242495"]}, {"Citation": "Zollner G., Trauner M. (2006). Molecular Mechanisms of Cholestasis. Wien Med. Wochenschr 156(13-14), 380\u2013385. 10.1007/s10354-006-0312-7", "ArticleIdList": ["10.1007/s10354-006-0312-7", "16937039"]}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "8", "Day": "14"}, {"Year": "2021", "Month": "11", "Day": "10"}, {"Year": "2021", "Month": "12", "Day": "20", "Hour": "6", "Minute": "18"}, {"Year": "2021", "Month": "12", "Day": "21", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "12", "Day": "21", "Hour": "6", "Minute": "1"}, {"Year": "2021", "Month": "1", "Day": "1"}], "PublicationStatus": "epublish", "ArticleIdList": ["34926449", "PMC8675020", "10.3389/fcell.2021.758632", "758632"]}}], "PubmedBookArticle": []}